Due to the need of early and emergency effective treatments for COVID-19, less attention
may have been paid to their safety during the global emergency. In addition, characteristics …

Background An urgent need for coronavirus infectious disease (COVID-19) treatment has
resulted in off-label drug use. Although previous studies had investigated the adverse drug …

The modulation of the pharmacological action of drugs due to drug-drug interactions (DDIs)
is a critical issue in healthcare. The aim of this study was to evaluate the prevalence and the …

Background Patients hospitalised with severe acute respiratory syndrome coronavirus 2
[SARS-CoV-2; coronavirus 2019 disease (COVID-19)] infection are frequently older with co …

Importance During the COVID-19 pandemic, urgent clinical management of patients has
mainly included drugs currently administered for other diseases, referred to as repositioned …

Drug-drug interactions (DDI) potentially occurring between medications used in the course
of COVID-19 infection and medications prescribed for the management of underlying …

Primary aim was to assess prevalence and severity of potential and real drug–drug
interactions (DDIs) among therapies for COVID-19 and concomitant medications in …

Introduction Since COVID-19 patients are often polytreated, monitoring drug–drug
interaction (DDIs) is necessary. We evaluated whether drugs used after the second COVID …

Introduction In the context of COVID-19 pandemic, a national pharmacovigilance survey was
set up in March 2020. The purpose of this survey was to ensure continuous monitoring of …

Objectives Coronavirus disease 2019 (COVID-19) is an emerging viral infection without any
approved treatment. Investigational therapies for COVID-19 may cause clinically important …